ReviewClinical pharmacokinetics2016
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Hirotoshi EchizenPubMed ↗Publisher ↗
No numbers read from the abstract.
104 papers cite itlatest 60 shown
this paperpooled ittrialcites it